Cellyan Biotechnology Co., Ltd (HKPD)
NASDAQ: HKPD · Real-Time Price · USD
0.646
-0.014 (-2.18%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Cellyan Biotechnology Ratios and Metrics
Market cap in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| Current | FY 2025 | FY 2024 | FY 2023 |
| Apr '26 Apr 28, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 |
| Market Capitalization | 15 | 12 | - | - |
| Enterprise Value | 15 | 14 | - | - |
| Last Close Price | 0.65 | 1.08 | - | - |
| PS Ratio | 0.93 | 0.59 | - | - |
| PB Ratio | 1.38 | 2.38 | - | - |
| P/TBV Ratio | 3.00 | 2.43 | - | - |
| P/FCF Ratio | - | 23.79 | - | - |
| P/OCF Ratio | - | 20.87 | - | - |
| EV/Sales Ratio | 0.92 | 0.68 | - | - |
| EV/EBITDA Ratio | - | 52.12 | - | - |
| EV/EBIT Ratio | - | 72.87 | - | - |
| EV/FCF Ratio | - | 27.77 | - | - |
| Debt / Equity Ratio | 0.44 | 0.48 | 0.49 | 1.18 |
| Debt / EBITDA Ratio | 4.86 | 1.88 | 0.80 | 0.41 |
| Debt / FCF Ratio | - | 4.76 | - | 0.43 |
| Net Debt / Equity Ratio | -0.04 | -0.13 | 0.35 | 0.28 |
| Net Debt / EBITDA Ratio | 0.39 | -2.37 | 0.85 | 0.16 |
| Net Debt / FCF Ratio | 0.42 | -1.26 | -3.28 | 0.10 |
| Asset Turnover | 1.65 | 2.25 | 2.76 | - |
| Inventory Turnover | 25.97 | 23.97 | 23.36 | - |
| Quick Ratio | 2.51 | 2.65 | 1.37 | 0.88 |
| Current Ratio | 2.93 | 2.99 | 2.46 | 1.08 |
| Return on Equity (ROE) | -13.38% | -0.58% | 54.96% | - |
| Return on Assets (ROA) | -3.94% | 1.31% | 17.28% | - |
| Return on Invested Capital (ROIC) | -12.64% | -2.83% | 44.93% | 127.37% |
| Return on Capital Employed (ROCE) | -9.40% | 2.90% | 30.40% | 114.30% |
| Earnings Yield | -4.62% | -0.23% | - | - |
| FCF Yield | -3.24% | 4.20% | - | - |
| Buyback Yield / Dilution | -19.69% | -38.56% | -7.64% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.